September 29, 2025
Vivace Therapeutics – Expanded Access Policy
Vivace Therapeutics is committed to developing innovative therapies for patients with cancer. Our priority is to conduct well-designed clinical trials that will generate the data needed to obtain regulatory approval and make our therapies broadly available.
At this time, Vivace Therapeutics does not provide access to its investigational products outside of participation in clinical trials. We believe that clinical trial participation is the most appropriate way for patients to access our therapies and ensures that use of our investigational products is consistent, carefully monitored, and aligned with regulatory standards.
Accordingly, Vivace Therapeutics does not accept or grant requests for expanded access to any of our investigational products. We encourage patients and physicians who are interested in our therapies to consider participation in one of our ongoing or future clinical trials.
Information about our clinical studies can be found at www.clinicaltrials.gov.
